Primary: * To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: * To assess the safety and tolerability of oxaliplatin * To assess time to progression and overall survival.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
11
Sanofi aventis administrative office
Bangkok, Thailand
Response rate
Time frame: Throughout the study period
Progression-free survival
Time frame: Throughout the study period
Overall survival
Time frame: Throughout the study period
Adverse events
Time frame: Throughout the study period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.